Rosiglitazone Maleate Background and Rosiglitazone Maleate FAQ

Many diabetes patients have had questions recently about Rosiglitazone Maleate, developed by the pharmaceutical company GlaxoSmithKlein, and approved in 1999 for administration to Type 2 diabetes patients. Rosiglitazone Maleate had been widely prescribed by doctors until the federal Food and Drug Administration (FDA) released extended warnings about the drug in May of 2007, citing a New England Journal of Medicine study that claims a greatly increased risk of heart attack for patients taking the drug. Many patients who were formerly taking Rosiglitazone Maleate now find themselves with questions as to what steps they should take now that Rosiglitazone Maleate may not be an entirely safe treatment option.

This page is intended as a resource for those with questions or concerns about Rosiglitazone Maleate.

Why would I be prescribed Rosiglitazone Maleate?

Rosiglitazone Maleate, also marketed under the brand name Avandia, is an anti-diabetic drug, prescribed to those diabetes patients with Type 2 (non-insular dependent) diabetes. It one of a few diabetes drugs in the Thiazolidinedione class that are prescribed by doctors to treat diabetes and help maintain healthy insulin patients. The drug is administered orally in form of Rosiglitazone Maleate tablets.

What should I do if I've been taking Rosiglitazone Maleate?

First off, any patient who has been taking Rosiglitazone Maleate should immediately consult with their doctor about the possibility of alternative treatment options. While the FDA has not explicitly ordered any sort of Rosiglitazone Maleate recall, given the medical study pointing to increased risk of heart attack, and the new FDA warnings about Rosiglitazone Maleate, there could exist a danger in continued usage of Rosiglitazone Maleate as a treatment for Type 2 diabetes.

Should I stop taking Rosiglitazone Maleate immediately?

The FDA has not expressly stated that Rosiglitazone Maleate is no longer an effective or safe treatment for Type 2 diabetes, but patients should exercise some degree of caution in ensuring they are endangering their health by continued use of Rosiglitazone Maleate.

Should I consider a Rosiglitazone Maleate lawsuit?

At present, no class-action Rosiglitazone Maleate lawsuit has been filed against the drug's manufacturer, however anyone interested in the possible legal ramifications of the FDA Rosiglitazone Maleate warning should contact an experienced Rosiglitazone Maleate attorney or Rosiglitazone Maleate law firm for more information.

Where can I find more information about the Rosiglitazone Maleate warning or a Rosiglitazone Maleate lawsuit?

Anyone who has taken Rosiglitazone Maleate should be at least mildly concerned about the revelatory findings in the New England Journal of Medicine study, and anyone with questions as to what the FDA Rosiglitazone Maleate warning might mean as far as any Rosiglitazone Maleate litigation can fill out the Rosiglitazone Maleate case evaluation form below, because in a situation such as this, having a knowledgeable Rosiglitazone Maleate lawyer could be very important.

Rosiglitazone Maleate Case Evaluation Form